NeuroPace (NPCE) Gains from Investment Securities (2020 - 2021)
NeuroPace (NPCE) posted quarterly Gains from Investment Securities of $2.1 million for Q2 2021, down 32.74% quarter-over-quarter from $3.1 million in Q1 2021.
NeuroPace (NPCE) Gains from Investment Securities (2020 - 2021) Analysis & Trends
NeuroPace's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $2.1 million for Q2 2021.
- In Q2 2021, Gains from Investment Securities changed N/A year-over-year to $2.1 million; the TTM figure through Mar 2022 stood at $2.1 million (down 28.6% YoY), while the FY2021 annual figure was $5.2 million, up 2992.82% from the prior year.
- Gains from Investment Securities for Q2 2021 stood at $2.1 million, down from $3.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $3.1 million in Q1 2021, with the low at -$181000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | NeuroPace | 478.49 Mn | 426.79 Mn | 18.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 2.10 Mn |
| Jun 30, 2021 | 2.10 Mn |
| Mar 31, 2021 | 3.12 Mn |
| Mar 31, 2021 | 3.12 Mn |
| Dec 31, 2020 | -181,000.00 |
| Dec 31, 2020 | -181,000.00 |